Cyclophosphamide-Bortezomib-Dexamethasone (CyBorD) With Daratumumab (DARA) (CyBorD-Dara)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02955810
Recruitment Status : Active, not recruiting
First Posted : November 4, 2016
Last Update Posted : March 29, 2018
Janssen Pharmaceuticals
Cancer Trials Ireland
Information provided by (Responsible Party):
Michael O'Dwyer, National University of Ireland, Galway, Ireland

No Study Results Posted on for this Study
  Recruitment Status : Active, not recruiting
  Estimated Primary Completion Date : September 2018
  Estimated Study Completion Date : November 2020